Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Systemic Treatment Options for Atopic Dermatitis
Author(s):
The panelist discusses how systemic atopic dermatitis (AD) treatment involves biologics and Janus kinase inhibitors for moderate to severe cases, targeting inflammation and itch with individualized approach based on patient factors, offering significant symptom improvement and skin barrier restoration.
Video content above is provided by the following:
- Describe your approach to initiating systemic treatment in patients with AD. At what point do you consider systemic treatment for your patients?
- Does your approach differ based on patient age or other factors?
- Briefly discuss the systemic agents that are currently FDA-approved for AD, including how they work to address itch and skin lesions, as well as efficacy and safety data.
- Dupilumab, lebrikizumab, tralokinumab, nemolizumab
- Abrocitinib, upadacitinib
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
